Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025

Name: Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Download Sample Buy Report

Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report 2025

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025 - By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy), By Stage (Stage I, Stage II, Stage III, Stage IV ), By End-User (Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025

Report Price : $4490.00 | Pages : 250 | Published : August 2025 | Delivery Time: 2-3 business days | Format :

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Regional Data

FAQs

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

• Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market size has reached to $1.25 billion in 2024

• Expected to grow to $1.57 billionin 2029 at a compound annual growth rate (CAGR) of 4.6%

• Growth Driver: Rising Adoption Of Targeted Cancer Therapy Fueling The Growth Of The Market Due To Advancements In Genetic Profiling

• Market Trends: FDA Approval Advances Immunotherapy For Gastric Cancer

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a subtype of gastric (stomach) or gastroesophageal junction cancer in which the cancer cells have higher than normal levels of the human epidermal growth factor receptor 2 (HER2) protein or gene amplification, which promotes cancer cell growth. This subtype can be targeted with specific therapies, improving treatment outcomes in eligible patients.

The main therapy types for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer are chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy uses powerful drugs that travel through the bloodstream to destroy fast-growing cancer cells, including those in HER2-positive gastric cancer. It is used for various stages, which include stage I, stage II, stage III, and stage IV, for varied end users such as ambulatory surgery centers, hospitals and specialty clinics, and others.

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size and growth rate 2025 to 2029: Graph

What Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size 2025 And Growth Rate?

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size has grown steadily in recent years. It will grow from $1.25 billion in 2024 to $1.31 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing utilization of companion diagnostics, rising awareness among oncologists about HER2 biomarkers, growing focus on personalized cancer therapies, rising interest in antibody-drug conjugates, and increasing reimbursement for targeted therapies.

What Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Forecast?

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size is expected to see steady growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing availability of molecular diagnostic labs, growing awareness campaigns for gastric cancer screening, rising next-generation sequencing (NGS) usage, growing demand for outpatient cancer care services, and increasing global regulatory approvals of HER2 drugs. Major trends in the forecast period include optimizing treatment sequences, nanotechnology in drug delivery, artificial intelligence in HER2 diagnostics, enhancing antibody-dependent cellular cytotoxicity, and advancements in immunotherapy combinations.

Book your 30 minutes free consultation with our research experts

How Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmented?

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy

2) By Stage: Stage I, Stage II, Stage III, Stage IV

3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines

2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, cancer vaccines, Cytokine-Based Therapies

3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy

4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors

What Is Driving The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market? Rising Adoption Of Targeted Cancer Therapy Fueling The Growth Of The Market Due To Advancements In Genetic Profiling

The rising adoption of targeted cancer therapy is expected to propel the growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market going forward. Targeted therapy, also known as personalized medicine, is a treatment approach that uses specific drugs or substances to block the growth of cancer by focusing on particular molecules involved in tumor development. The rise in targeted therapy use is largely due to advancements in genetic profiling, which allow for more precise treatments based on an individual's unique tumor characteristics, leading to improved effectiveness and fewer side effects. In HER2-positive gastric cancer, targeted therapy is used by directly attacking the HER2 protein, which is overexpressed in these tumors, slowing disease progression and enhancing patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration (FDA) approved 16 new personalized medicines, including 7 drugs for cancer and 3 for various other diseases and conditions in 2023, indicating an increase from 6 in 2022. Therefore, the rising adoption of targeted cancer therapy is driving the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry.

Who Are The Major Players In The Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

What Are The Key Trends Of The Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market? FDA Approval Advances Immunotherapy For Gastric Cancer

Major companies operating in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are focusing on gaining approvals for innovative therapies such as advanced immunotherapy-enhanced combination regimens, such as the integration of immune checkpoint inhibitors with targeted therapy and chemotherapy, to significantly improve patient outcomes in first-line treatment settings. The advanced immunotherapy-enhanced combination regimens approach leverages the body's immune system by inhibiting programmed death (PD)-1 or programmed death (PD)-L1 interaction while simultaneously targeting HER2 receptors and using chemotherapeutic agents, thereby amplifying anti-tumor activity and enhancing survival rates. For instance, in March 2025, Merck & Co., Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda), in combination with trastuzumab and chemotherapy, as a first-line treatment for adults with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death (PD)-L1. This newly approved combination therapy demonstrated a substantial improvement in median progression-free survival and overall survival compared to standard regimens. With a higher overall response rate of 73% and a longer median duration of response, the treatment represents a paradigm shift in managing advanced HER2-positive gastric cancers.

What Are Latest Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market? Pfizer’s Acquisition Of Seagen Enhances Targeted Therapies

In December 2023, Pfizer Inc., a US-based pharmaceutical industry company, acquired Seagen Inc. for an undisclosed amount. Through this acquisition, Pfizer Inc. aims to strengthen its oncology portfolio, enhance its capabilities in targeted cancer therapies. Seagen Inc. is a US-based biotechnology company that specializes in HER2-positive gastric cancer treatments.

What Is The Regional Outlook For The Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

North America was the largest region in the acute care telemedicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Care Telemedicine Market?

The acute care telemedicine market includes revenues earned by entities by providing services like virtual emergency care, remote intensive care unit monitoring, tele-stroke evaluations, virtual hospitalist support, and real-time specialist consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Industry?

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including human epidermal growth factor receptor 2 (HER2)-positive gastric cancer global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry. This market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Author: Abdul Wasay

Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.31 billion
Revenue Forecast In 2034	$1.57 billion
Growth Rate	CAGR of 4.6% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	Therapy, Stage, End-User, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Characteristics

3. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Trends And Strategies

4. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Rate Analysis

5.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Total Addressable Market (TAM)

6. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmentation

6.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chemotherapy

Immunotherapy

Radiation Therapy

Targeted Therapy

6.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Stage I

Stage II

Stage III

Stage IV

6.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ambulatory Surgery Centers

Hospitals And Specialty Clinics

Other End-Users

6.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Fluoropyrimidines

Platinum-Based Agents

Taxanes

Irinotecan

Anthracyclines

6.5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immune Checkpoint Inhibitors

Monoclonal Antibodies

Cancer Vaccines

Cytokine-Based Therapies

6.6. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

External Beam Radiation Therapy

Intensity-Modulated Radiation Therapy

Stereotactic Body Radiation Therapy

3D Conformal Radiation Therapy

6.7. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

HER2-Targeted Therapies

Tyrosine Kinase Inhibitors

Antibody-Drug Conjugates

mTOR Inhibitors

PI3K/AKT/mTOR Pathway Inhibitors

7. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Regional And Country Analysis

7.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

8.1. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

9.1. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

9.2. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

10.1. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

11.1. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

11.2. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

12.1. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

13.1. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

14.1. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

14.2. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

15.1. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

15.2. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

16.1. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

17.1. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

18.1. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

19.1. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

20.1. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

21.1. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

21.2. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

22.1. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

23.1. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

23.2. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

24.1. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

24.2. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

25.1. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

25.2. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

26.1. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

26.2. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

27.1. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

28.1. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

28.2. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

29.1. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

29.2. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape And Company Profiles

30.1. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape

30.2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company

31.2. AstraZeneca PLC

31.3. Novartis AG

31.4. Amgen Inc.

31.5. Astellas Pharma Inc.

31.6. Daiichi Sankyo Company Limited

31.7. Genentech Inc.

31.8. Ono Pharmaceutical Co Ltd.

31.9. Shanghai Henlius Biotech Inc.

31.10. MacroGenics Inc.

31.11. Hutchison Medipharma Limited

31.12. ALX Oncology Holdings Inc.

31.13. Taiho Pharmaceutical Co Ltd.

31.14. Ambrx Biopharma Inc.

31.15. LintonPharm Co Ltd.

32. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

34. Recent Developments In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

35. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market High Potential Countries, Segments and Strategies

35.1 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Countries Offering Most New Opportunities

35.2 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Segments Offering Most New Opportunities

35.3 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Pfizer Inc. Financial Performance

Table 79: Roche Holding AG Financial Performance

Table 80: Merck & Co Inc. Financial Performance

Table 81: Bayer Aktiengesellschaft Financial Performance

Table 82: Eli Lilly and Company Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Pfizer Inc. Financial Performance

Figure 79: Roche Holding AG Financial Performance

Figure 80: Merck & Co Inc. Financial Performance

Figure 81: Bayer Aktiengesellschaft Financial Performance

Figure 82: Eli Lilly and Company Financial Performance

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

How the Nerve Growth Factor Global Market Report 2025 Market Will Grow: Key Trends, Market Size, and Opportunities Beyond 2025

Obeticholic Acid Global Market Report 2025 Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

Unlocking Opportunities in the Phosphoramidite Global Market Report 2025 Market: Key Trends, Market Growth, and Forecast Insights

Personalized Cancer Vaccines Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Disease Drugs, Vaccine, Therapeutic Nutrients And Mineralsa) Cardiovascular Drugs Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti-Thrombotic, Angina Pectoris, Congestive Heart Failure, Other Cardiovascular Drugsb) Dermatology Drugs Type (Acne Drugs, Dermatitis Drugs, Psoriasis Drugs, Other Drugs For Dermatology Diseasesc) Gastrointestinal Drugs Type (Antacids, Antiulcerants, Antiemetics And Antinauseants, Antidiarrhealsd) Genito-Urinary Drugs Type (Hormonal Contraceptives, Drugs For Benign Prostatic Hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction

View Report

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Other Oncology Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other Distribution Channels), By Route Of Administration (Oral, Parental, Other Route Of Administration), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2032

View Report

Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Respiratory Diseases Drugs Global Market Report 2022 – By Type (Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Gastrointestinal Drugs Global Market Report 2022 – By Type (Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Hematology Drugs Global Market Report 2022 – By Type (Blood Products, Anemia And Other Blood Disorder Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Frequently Asked Questions

What is the definition of the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market?

How will the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market drivers and restraints affect the market dynamics? What forces will shape the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer industry going fo

The Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market major growth driver - Rising Adoption Of Targeted Cancer Therapy Fueling The Growth Of The Market Due To Advancements In Genetic Profiling. For further insights on the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market, request a sample here

What is the forecast market size or the forecast market value of the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market?

The Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market size has grown strongly in recent years. The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size has grown steadily in recent years. It will grow from $1.25 billion in 2024 to $1.31 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing utilization of companion diagnostics, rising awareness among oncologists about HER2 biomarkers, growing focus on personalized cancer therapies, rising interest in antibody-drug conjugates, and increasing reimbursement for targeted therapies. The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size is expected to see steady growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing availability of molecular diagnostic labs, growing awareness campaigns for gastric cancer screening, rising next-generation sequencing (NGS) usage, growing demand for outpatient cancer care services, and increasing global regulatory approvals of HER2 drugs. Major trends in the forecast period include optimizing treatment sequences, nanotechnology in drug delivery, artificial intelligence in HER2 diagnostics, enhancing antibody-dependent cellular cytotoxicity, and advancements in immunotherapy combinations. For further insights on the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market, request a sample here

How is the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market segmented?

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors For further insights on the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market, request a sample here

Which region has the largest share of the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market? What are the other regions covered in the report?

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market, request a sample here.

Who are the major players in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market?

What are the key trends in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market?

Major trends in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market include FDA Approval Advances Immunotherapy For Gastric Cancer. For further insights on the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market, request a sample here.

What are the major opportunities in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market? What are the strategies for the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market?

For detailed insights on the major opportunities and strategies in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market, request a sample here.

How does the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market relate to the overall economy and other similar markets?

For detailed insights on Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer industry?

For detailed insights on the mergers and acquisitions in the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer industry, request a sample here.

What are the key dynamics influencing the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market growth? SWOT analysis of the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market.

For detailed insights on the key dynamics influencing the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer market growth and SWOT analysis of the Human Epidermal Growth Factor Receptor 2 HER2 Positive Gastric Cancer industry, request a sample here.

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025

Market Insights

Related Reports

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

What Is Covered Under Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

What’s The Trade War Impact On Pharmaceuticals Industry?

What Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size 2025 And Growth Rate?

What Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Forecast?

How Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmented?

What Is Driving The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market? Rising Adoption Of Targeted Cancer Therapy Fueling The Growth Of The Market Due To Advancements In Genetic Profiling

Who Are The Major Players In The Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

What Are The Key Trends Of The Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market? FDA Approval Advances Immunotherapy For Gastric Cancer

What Are Latest Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market? Pfizer’s Acquisition Of Seagen Enhances Targeted Therapies

What Is The Regional Outlook For The Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

What Defines the Acute Care Telemedicine Market?

How is Market Value Defined and Measured?

What is the Market Assessment and Strategic Outlook for the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Industry?

Table Of Contents

List Of Tables

List Of Figures

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

How the Nerve Growth Factor Global Market Report 2025 Market Will Grow: Key Trends, Market Size, and Opportunities Beyond 2025

Obeticholic Acid Global Market Report 2025 Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

Unlocking Opportunities in the Phosphoramidite Global Market Report 2025 Market: Key Trends, Market Growth, and Forecast Insights

Personalized Cancer Vaccines Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

Frequently Asked Questions